MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Search

Pacific Biosciences of California Inc

Closed

SectorHealthcare

1.28 3.23

Overview

Share price change

24h

Current

Min

1.2

Max

1.3

Key metrics

By Trading Economics

Income

-428M

-426M

Sales

-2.1M

37M

EPS

-0.15

Profit margin

-1,146.812

Employees

575

EBITDA

-420M

-403M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+74.19% upside

Dividends

By Dow Jones

Next Earnings

6 sie 2025

Market Stats

By TradingEconomics

Market Cap

18M

357M

Previous open

-1.95

Previous close

1.28

News Sentiment

By Acuity

100%

0%

369 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Pacific Biosciences of California Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 lip 2025, 23:09 UTC

Earnings

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 lip 2025, 19:16 UTC

Acquisitions, Mergers, Takeovers

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 lip 2025, 23:47 UTC

Market Talk

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 lip 2025, 23:41 UTC

Market Talk

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 lip 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 lip 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 lip 2025, 22:21 UTC

Acquisitions, Mergers, Takeovers

James Hardie Completes Acquisition of AZEK

1 lip 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1 lip 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 lip 2025, 20:24 UTC

Earnings

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 lip 2025, 19:55 UTC

Market Talk

Oil Futures Resume Cautious Rally -- Market Talk

1 lip 2025, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 lip 2025, 19:12 UTC

Market Talk

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 lip 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 lip 2025, 18:41 UTC

Acquisitions, Mergers, Takeovers

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 lip 2025, 18:33 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

1 lip 2025, 18:33 UTC

Market Talk

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 lip 2025, 18:32 UTC

Market Talk

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 lip 2025, 18:22 UTC

Market Talk

Remittances to Mexico Down in May -- Market Talk

1 lip 2025, 17:45 UTC

Market Talk

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 lip 2025, 17:01 UTC

Acquisitions, Mergers, Takeovers

Danone Completed Acquisition of Majority Stake in Kate Farms

1 lip 2025, 16:55 UTC

Earnings

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 lip 2025, 16:27 UTC

Market Talk

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 lip 2025, 16:25 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 lip 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

1 lip 2025, 15:48 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 lip 2025, 15:46 UTC

Market Talk

Global Equities Roundup: Market Talk

1 lip 2025, 15:46 UTC

Market Talk

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 lip 2025, 14:54 UTC

Market Talk

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 lip 2025, 14:49 UTC

Market Talk

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Peer Comparison

Price change

Pacific Biosciences of California Inc Forecast

Price Target

By TipRanks

74.19% upside

12 Months Forecast

Average 2.16 USD  74.19%

High 3 USD

Low 1.25 USD

Based on 8 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

5

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

1.13 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

369 / 380 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.